Targeting enhanced cell death represents a potential therapeutic strategy for VEXAS syndrome.

This study confirms increased cell death of monocytes and neutrophils and damage-associated molecular patterns in VEXAS syndrome, and these findings may be valuable for drug screening, therapeutic strategies and as biomarkers.